OLEMA PHARMACEUTICALS, INC. Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit of $4.82 per share for the 1-month period ending 2020-09-30, per its 10-K filed 2023-03-09.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit · last filed 2023-03-09
- 2020-09-30: Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit 1 month $4.82.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit 1 month |
|---|---|
| 2020-09-30 | $4.82 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |